Cosciens Biopharma Inc. · TSX:CSCI
Cosciens Biopharma — Aeterna Zentaris — Investor Presentation (October 2021)
29 slides from Cosciens Biopharma's investor presentation, Oct 7, 2021
Slide 1: In Pursuit of Medical Innovations: Corporate Presentation
zentaris.com NASDAQ: AEZS / TSX: AEZS Exhibit 99.1 ALTERNA ZENTARIS In Pursuit of Medical Innovations October 2021 Corporate Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements This document contains forward looking statements (as defined by applicable securities legislation) made pursuant to the safe harbor provision of the US Securities Litigation Reform Act of 1995 and forward looking information (as defined under applicable Canadian securitie
Slide 3: | Diversified portfolio focused on areas | Leveraging network of large pharmaceutical
| Diversified portfolio focused on areas | Leveraging network of large pharmaceutical of significant unmet medical need and university partners and collaborators Executing strategy to deliver multiple Strong financial position with runway development and regulatory milestones expected to fund operat
Slide 4: Diagnostic Commercial and Development Pipeline
Diagnostic Commercial and Development Pipeline Commercial Rights Program Indication Preclinical Phase1 Phase2 Phase3 Commercial U.S./Canada Europe Israel ROW g | | 12) : ___ | Adult Growth Hormone ait Gonsiient MeyaPhant) PATERNA > Macimorelin Deficiency (AGHD) roe Hack @ A ae ZENTARIS (2) c D Child
Slide 5: Therapeutic and Vaccine Development Pipeline
Therapeutic and Vaccine Development Pipeline Program Indication Preclinical Phase1 Phase2 Phase3 ~~ Program Highlights Neuromyelitis Optica Spectrum Disorder In-licensed program in January 2021 a 7) AIM Biologicals aNmosn) WUREBURG. s Parkinson's Disease In-licensed program in September 2021 a (eb)
Slide 6: Development Programs
Development Programs Advancing Therapeutics and Vaccines to Secure Long-Term Growth 6G ALTERNA ZENTARIS
Slide 7: AIM Biologicals technology platform for auto-immune diseases
Technology platform enabling highly specific treatment for auto-immune diseases with well-defined target antigens Modulation of immune response towards auto- antigens by induction of antigen-specific regulatory T cells and by elimination of cognate antigen- specific cytotoxic T cells vnsemm Entered
Slide 8: The Promise of Targeted, Physiological, Antigen-Specific Immunomodulation
The Promise of Targeted, Physiological, Antigen-Specific Immunomodulation Autoimmune Diseases Enhanced by autoreactive effector T cells Ameliorated by protective effector T cells x Immunosuppressive Therapeutics Reduce disease symptoms Often cause severe side effects & AIM Biologics Antigen-specific
Slide 9: AIM Biologicals Concept
AIM Biologicals Concept’ « Adaptable platform of immunomodulating molecules * Soluble 5 R2m fusion proteins feocemiinem-speptide (= antigen)mvnlea) is coupled to the proteins via a |inker * The proteins interacts with the target be cells via the T-cell receptor (TCR) and s ILT-2 to induce immune tol
Slide 10: The Promise of Targeted, Physiological, Antigen-Specific Immunomodulation
The Promise of Targeted, Physiological, Antigen-Specific Immunomodulation Potential selective treatment option for Potential treatment option for Parkinson’s <p> neuromyelitis optica spectrum disorder disease (PD) (NMOSD) Se Well-defined antigen: Aquaporin-4 (AQP4) Go) a-Synuclein (a-Syn) described
Slide 11: AEZS-150: Delayed Clearance Parathyroid Hormone Fusion Polypeptide
AEZS-150: Delayed Clearance Parathyroid Hormone (DC-PTH) Fusion Polypeptide Hypoparathyroidism Body produces abnormally low levels of PTH ZN PTH is a key regulating hormone ly) essential for calcium homeostasis and - Indepth characterization of development candidate renal phosphate clearance ace) Or
Slide 12: AEZS-150: Delayed Clearance Parathyroid Hormone Fusion Polypeptide
AEZS-150: Delayed Clearance Parathyroid Hormone (DC-PTH) Fusion Polypeptide AEZS-150: Fusion-Protein of PTH [1-34] coupled via a linker to a modified growth-hormone binding protein (GHBP)! Delayed clearance in comparison to PTH[1-34] Potential to control serum calcium levels by once weekly treatment
Slide 13: Oral coronavirus vaccine based on Salmonella typhi Ty21a
Potential for temperature stable ye 2° °o1 Orally active live-attenuated bacterial supply chain: ~2°C - 8°C vaccine based on the Salmonella typhi Ty21a carrier strain currently used as a fyphaldivaceine Potential to induce systemic and mucosal immunity to prevent infection r| inmate This new, altern
Slide 14: Pre-clinical studies for prevention of coronavirus diseases
Currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including “y 1 Chey ( COVID-19 (SARS-CoV-2) Reo er ae \ Modified Integration of 1 or Salmonella typhi Ty21a SARS-CoV-2 antigens - Antigen 2 an Adaptable Plasmid Vector Induction of Immunity Multiple-Antigens Potent
Slide 15: Development Plan Towards Phase 1: Oral Coronavirus Vaccine
Development Plan Towards Phase 1 Oral Coronavirus Vaccine H1 2023: Planned start of clinical development for oral vaccine Pre-clinical safety and toxicology assessment Manufacturing process, assessment / development Virus challenge experiments in immunized transgenic animals In-vivo immunology exper
Slide 16: Chlamydia trachomatis oral vaccine
‘ Modified Antigen 2 Salmonella typhi Adaptable Ty2ta Plasmid Vector strain Integration of 1 or 2 Chlamydia trachomatis antigens + Chlamydia trachomatis is a sexually transmitted gram- negative bacterium infecting over 130 million subjects annually + Whereas symptomatic infection can be treated by a
Slide 17: Macimorelin as potential treatment for ALS
THE UNIVERSITY OF QUEENSLAND AUSTRALIA Exclusive rights for AEZS to Investigation as a potential University researchers to negotiate a license agreement for the treatment for Amyotrophic Lateral Sclerosis (ALS, Lou secure grants and conduct commercial use of the results Gehrig's disease) pre-clinica
Slide 18: Roadmap for Advancing Development Programs Towards IND Filing
Roadmap for Advancing Development Programs Towards IND Filing Pre-clinical Development Establish Experimental Establish Transfer joint pre- work in-vitro Select Formalized clinical FDA of program clinical and in-vivo development pre-clinical development _ pre-IND information teams models candidate d
Slide 19: Macimorelin / Macrilen: A Disruptive Oral Diagnostic Test
19 Macimorelin / Macrilen™ A Disruptive Oral Diagnostic Test Solution for Growth Hormone Deficiency First and only AGHD test approved by US FDA and European Commission AETERNA ZENTARIS
Slide 20: Growth hormone produced by the pituitary gland
Produced by the pituitary gland 20 (located at the base of the brain)
Slide 21: No Other FDA or EC Approved Oral Test
No Other FDA or EC Approved Oral Test Insulin tolerance test (ITT) considered ‘[ITT Test] is increasingly used less the “Gold Standard” in GHD detection frequently in the U.S. because of procedures"? safety concerns.”? Not FDA or EC approved or regulated 2: AACE 2019 Guidelines: American Association
Slide 22: Pediatric GHD Phase 3 study design
Open-label, single dose, multicenter, multinational US, Czech Republic, Germany, Poland, Georgia, Italy, Serbia, Romania, Russia, Slovenia and Ukraine Macimorelin GHST will be performed twice (for repeatability data) Two standard GHSTs as controls: arginine (i.v.), clonidine (p.o.) Design suitable t
Slide 23: Macimorelin Commercial Rights
Macimorelin Commercial Rights Actively seeking commercial partners in ROW novo nordisk License and Assignment Agreement Territories: United States and Canada Royalties on sales Sales milestones Aeterna Zentaris controls API supply chain and provides API Co-development for expansion into CGHD + Novo
Slide 24: Expected Value Driving Milestones
Expected Value Driving Milestones v Commenced pivotal Phase 3 safety and efficacy study (DETECT-trial) v Option exercise and in- licensing of Chlamydia as second vaccine indication Planned submission - FDA and EMA CGHD dossiers Q2/Q3 2021 July 2022 2022 Planned completion of P02 DETECT CGHD study ac
Slide 25: Corporate Overview
Corporate Overview ETERNA 25 ZENTARIS
Slide 26: Cash on Hand and Shares Outstanding
~121M Cash on Hand 4 i Shares 3 month As of June 30, 2021 Outstanding’ Avg. Volume"
Slide 27: Management team
Leslie Auld, CPA, Nicola Ammer, MD € Michael Teifel, PhD MBA ‘ SVP Clinical < SVP Non-Clinical SVP, Chief Financial Development, Development, Officer Chief Medical Officer : Chief Scientific Officer
Slide 28: Investment Summary
Investment Summary Advancing diversified pipeline across multiple high-value therapeutic areas Only oral drug indicated High-Value Focus Areas: Leveraging network of for diagnosis of adult growth hormone deficiency large pharmaceutical Endocrine disorders Auto-immune diseases : . and university part
Slide 29: Investor & Media Relations
zentaris.com NASDAQ: AEZS / TSX: AEZS ALTERNA ZENTARIS In Pursuit of Medical Innovations Investor & Media Relations JTC Team 833.475.8247 aezs@jtcir.com
Aeterna Zentaris — Investor Presentation (October 2021) on 6ix